Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more
Algorae Pharmaceuticals Ltd (1AI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.327x
Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has a cash flow conversion efficiency ratio of -0.327x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-618.21K) by net assets (AU$1.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Algorae Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Algorae Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Algorae Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SOFTOX SOLUTIONS NK 002
F:6FV
|
N/A |
|
Indiana Resources Ltd
AU:IDA
|
-0.785x |
|
Airo Lam limited
NSE:AIROLAM
|
0.083x |
|
PT Master Print Tbk
JK:PTMR
|
-0.059x |
|
Nila Infrastructures Limited
NSE:NILAINFRA
|
-0.083x |
|
Bonia Corporation Bhd
KLSE:9288
|
0.021x |
|
MSP Recovery Inc.
NASDAQ:LIFW
|
-0.008x |
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
0.032x |
Annual Cash Flow Conversion Efficiency for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Algorae Pharmaceuticals Ltd from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$2.23 Million | AU$-785.25K | -0.352x | -22.91% |
| 2024-06-30 | AU$5.31 Million | AU$-1.52 Million | -0.287x | +16.52% |
| 2023-06-30 | AU$5.78 Million | AU$-1.99 Million | -0.343x | +32.16% |
| 2022-06-30 | AU$4.03 Million | AU$-2.04 Million | -0.506x | +52.31% |
| 2021-06-30 | AU$1.38 Million | AU$-1.46 Million | -1.061x | +1.77% |
| 2020-06-30 | AU$2.88 Million | AU$-3.11 Million | -1.080x | -124.63% |
| 2019-06-30 | AU$4.14 Million | AU$-1.99 Million | -0.481x | +3.88% |
| 2018-06-30 | AU$7.14 Million | AU$-3.57 Million | -0.500x | -11.63% |
| 2017-06-30 | AU$7.52 Million | AU$-3.37 Million | -0.448x | +19.40% |
| 2016-06-30 | AU$5.68 Million | AU$-3.16 Million | -0.556x | +20.52% |
| 2015-06-30 | AU$5.13 Million | AU$-3.59 Million | -0.700x | -7056.25% |
| 2014-06-30 | AU$8.43 Million | AU$-82.44K | -0.010x | -109.69% |
| 2013-06-30 | AU$13.25 Million | AU$1.34 Million | 0.101x | +158.23% |
| 2012-06-30 | AU$14.35 Million | AU$-2.49 Million | -0.173x | +79.53% |
| 2011-06-30 | AU$6.76 Million | AU$-5.72 Million | -0.847x | +9.92% |
| 2010-06-30 | AU$6.24 Million | AU$-5.86 Million | -0.940x | +8.93% |
| 2009-06-30 | AU$5.53 Million | AU$-5.70 Million | -1.032x | -111.67% |
| 2008-06-30 | AU$11.48 Million | AU$-5.60 Million | -0.487x | +87.66% |
| 2007-06-30 | AU$1.40 Million | AU$-5.54 Million | -3.951x | -7.34% |
| 2006-06-30 | AU$1.80 Million | AU$-6.61 Million | -3.681x | -89.36% |
| 2005-06-30 | AU$3.14 Million | AU$-6.09 Million | -1.944x | -302.54% |
| 2004-06-30 | AU$-1.33 Million | AU$-1.27 Million | 0.960x | -- |